Literature DB >> 17123790

Differences in blood pregnenolone and dehydroepiandrosterone levels between schizophrenia patients and healthy subjects.

Michael Ritsner1, Rachel Maayan, Anatoly Gibel, Abraham Weizman.   

Abstract

BACKGROUND AND
OBJECTIVE: Contradictory and confusing reports on serum dehydroepiandrosterone (DHEA) levels in schizophrenia led us to compare the serum concentration of its precursor, pregnenolone (PREG), between medicated schizophrenia patients and healthy subjects. The neurosteroid levels were monitored for two months and the relationship of these neurosteroids with schizophrenic symptomatology, emotional distress, and anxiety was examined.
METHOD: We determined blood levels of PREG, and DHEA in 15 schizophrenia patients and 12 healthy controls at four time points: at the start of the study, after 2, 4 and 8 weeks. Analysis of covariance and canonical correlations across four time points were applied.
RESULTS: Controlling for age, serum concentrations of PREG were lower, while the DHEA level and the molar ratio values of DHEA/PREG were higher in schizophrenia patients compared to healthy controls. Both levels of PREG and DHEA and their molar ratio did not change significantly during the study's period either among schizophrenia patients or healthy controls. The blood levels of PREG appear to be associated with trait-anxiety scores in the schizophrenia patients, while associations of clinical symptoms with two neurosteroids did not reach a significant level when the confounding effect of emotional distress, and anxiety scores was controlled.
CONCLUSION: Low serum pregnenolone concentrations in schizophrenia appear to be associated with trait-anxiety scores independent of symptoms. Further research into the role of pregnenolone in schizophrenia is warranted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17123790     DOI: 10.1016/j.euroneuro.2006.10.001

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  14 in total

1.  Pregnenolone-progesterone-allopregnanolone pathway as a potential therapeutic target in first-episode antipsychotic-naïve patients with schizophrenia.

Authors:  HuaLin Cai; Xiang Zhou; George G Dougherty; Ravinder D Reddy; Gretchen L Haas; Debra M Montrose; Matcheri Keshavan; Jeffrey K Yao
Journal:  Psychoneuroendocrinology       Date:  2018-02-07       Impact factor: 4.905

Review 2.  Sex differences in schizophrenia, bipolar disorder, and post-traumatic stress disorder: Are gonadal hormones the link?

Authors:  Andrea Gogos; Luke J Ney; Natasha Seymour; Tamsyn E Van Rheenen; Kim L Felmingham
Journal:  Br J Pharmacol       Date:  2019-03-14       Impact factor: 8.739

3.  Simultaneous quantification of GABAergic 3alpha,5alpha/3alpha,5beta neuroactive steroids in human and rat serum.

Authors:  Patrizia Porcu; Todd K O'Buckley; Sarah E Alward; Christine E Marx; Lawrence J Shampine; Susan S Girdler; A Leslie Morrow
Journal:  Steroids       Date:  2009-01-13       Impact factor: 2.668

Review 4.  Pregnenolone, dehydroepiandrosterone, and schizophrenia: alterations and clinical trials.

Authors:  Michael S Ritsner
Journal:  CNS Neurosci Ther       Date:  2010       Impact factor: 5.243

5.  Progesterone reduces hyperactivity of female and male dopamine transporter knockout mice.

Authors:  Cheryl A Frye; Ichiro Sora
Journal:  Behav Brain Res       Date:  2010-01-20       Impact factor: 3.332

6.  Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia.

Authors:  Christine E Marx; Jimmy Lee; Mythily Subramaniam; Attilio Rapisarda; Dianne C T Bautista; Edwin Chan; Jason D Kilts; Robert W Buchanan; Eu Pui Wai; Swapna Verma; Kang Sim; Jayaraman Hariram; Rajesh Jacob; Richard S E Keefe; Siow Ann Chong
Journal:  Psychopharmacology (Berl)       Date:  2014-07-17       Impact factor: 4.530

Review 7.  Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS).

Authors:  Nicole Maninger; Owen M Wolkowitz; Victor I Reus; Elissa S Epel; Synthia H Mellon
Journal:  Front Neuroendocrinol       Date:  2008-12-03       Impact factor: 8.606

8.  Targeting the Immune System with Pharmacotherapy in Schizophrenia.

Authors:  Jennifer K Melbourne; Benjamin Feiner; Cherise Rosen; Rajiv P Sharma
Journal:  Curr Treat Options Psychiatry       Date:  2017-04-18

Review 9.  The Enigma of the Adrenarche: Identifying the Early Life Mechanisms and Possible Role in Postnatal Brain Development.

Authors:  Angela L Cumberland; Jonathan J Hirst; Emilio Badoer; Stefan A Wudy; Ronda F Greaves; Margaret Zacharin; David W Walker
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

10.  Pregnenolone rescues schizophrenia-like behavior in dopamine transporter knockout mice.

Authors:  Peiyan Wong; Cecilia Chin Roei Chang; Christine E Marx; Marc G Caron; William C Wetsel; Xiaodong Zhang
Journal:  PLoS One       Date:  2012-12-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.